Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 1999

View Archived Issues

Roche and Genentech relationship unaffected by public offering; Genentech provides Q3 update

Licensing opportunity from NIH: aspartic HIV protease inhibitors

Atlantic reports analgesic effects of CT-3 in mouse model

Teva announces possible acquisition of Novopharm

Orphan Medical completes licensing agreement with Pierre Fabre

Vasogen cleared to proceed with psoriasis clinical trial

Expanded agreement between Vertex and HMR receives Hart-Scott-Rodino clearance

Centocor submits sBLA to FDA for Remicade as treatment of rheumatoid arthritis

StressGen completes clinical trial with lead product during third quarter

Roche patents new compounds with MDM2-antagonist activity useful for treatment of tumors

Galderma describes new apoptosis-inducing antitumor agents

Novel prostaglandin analogues useful for bone disorders, glaucoma

Retinoid receptor-active compounds from Galderma for skin disorders

Neuroprotective fullerene derivatives designed by Aventis R&T

EASD highlights: novel aldose reductase inhibitor effective in model of diabetic neuropathy

Wilex and Ludwig Institute collaborate on clinical development of G250

Sonus's lead ultrasound contrast agent moves closer to commercialization

Chemosensitizing agent from Procept enters phase II for multiple myeloma

Phase II clinical trials initiated for humanized anti-CD3 antibody developed at PDL

First prescription drug approved in U.K. for severe PMS

Proof-of-concept trial begins for Vivus's oral PE compounds

The antidementia drug donepezil may also be beneficial in Lewy body dementia

Neuroprotective effects demonstrated for mglu receptor agonists in vitro and in vivo

Increasing NO levels in blood as novel strategy for sickle cell disease

Xyrem headed for NDA submission in a year

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...